Susquehanna International Group, LLP Hille Vax, Inc. Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$10.35 - $17.11 $133,618 - $220,890
12,910 New
12,910 $207,000
Q1 2023

May 16, 2023
BUY
$14.73 - $18.18 $155,239 - $191,599
10,539 New
10,539 $174,000
Q2 2022

Aug 15, 2022
BUY
$8.7 - $20.18 $199,142 - $461,920
22,890 New
22,890 $250,000

Others Institutions Holding HLVX

# of Institutions
93
Shares Held
40.5M
Call Options Held
0
Put Options Held
0
View Full List

About HilleVax, Inc.

HLVX Quotes by TradingView
  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $58.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email